Christopher Hoimes DO, PhD

Christopher Hoimes, DO, Ph.D., joined the genitourinary oncology program at Duke Cancer Institute as Associate Professor of Medicine where he will serve as a clinical investigator with a focus on GU cancers, experimental therapeutics, and early phase trials.

Dr. Hoimes has expertise in immunotherapy and biomedical engineering to advance cancer treatment and diagnostics. As director of GU malignancies at the Case Comprehensive Cancer Center at Seidman in Cleveland, OH, he built research teams that integrated radiologists, pathologists, and urologists with experts in biomedical engineering for novel imaging and drug development approaches. He has a particular interest in clinical and preclinical applications of nanomaterials for drug delivery and imaging, antibody-drug conjugates, and immune engineering. As a clinical investigator in Phase I and genitourinary malignancies, Hoimes serves as principal investigator of over 12 active Phase I, II, and III trials. He served on the NCCN guidelines panel for bladder and penile cancers serves on the SITC expert consensus panel for immunotherapy in bladder cancer and was a founding member of the NCCN panel on cancer immunotherapy and related complications.

Dr. Hoimes is board certified in Medical Oncology and Internal Medicine and was previously on faculty at Case Western Reserve University and Yale University. He received his medical degree from New York College of Osteopathic Medicine and completed Internal Medicine Residency and Chief at Penn State University and fellowship in Medical Oncology at Yale University School of Medicine.